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ABSTRACT
Objective: To explore women’s experiences of taking
adjuvant endocrine therapy as a treatment for breast
cancer and how their beliefs about the purpose of the
medication, side effects experienced and interactions
with health professionals might influence adherence.
Design: Qualitative study using semistructured, one-to-
one interviews.
Setting: 2 hospitals from a single health board in
Scotland.
Participants: 30 women who had been prescribed
tamoxifen or aromatase inhibitors (anastrozole or
letrozole) and had been taking this medication for
1–5 years.
Results:Women clearly wished to take their adjuvant
endocrine therapy medication as prescribed, believing
that it offered them protection against breast cancer
recurrence. However, some women missed tablets and
did not recognise that this could reduce the efficacy of
the treatment. Women did not perceive that healthcare
professionals were routinely or systematically monitoring
their adherence. Side effects were common and impacted
greatly on the women’s quality of life but did not always
cause women to stop taking their medication, or to seek
advice about reducing the side effects they experienced.
Few were offered the opportunity to discuss the impact of
side effects or the potential options available.
Conclusions: Although most women in this study took
adjuvant endocrine therapy as prescribed, many endured
a range of side effects, often without seeking help.
Advice, support and monitoring for adherence are not
routinely offered in conventional follow-up settings.
Women deserve more opportunity to discuss the pros,
cons and impact of long-term adjuvant endocrine
therapy. New service models are needed to support
adherence, enhance quality of life and ultimately improve
survival. These should ideally be community based, in
order to promote self-management in the longer term.
INTRODUCTION
Adjuvant endocrine therapy has been the
mainstay of breast cancer management
over the past three decades.1 Approximately
80% of breast cancers are oestrogen
receptor-positive and treated with tamoxifen
or, for postmenopausal women, aromatase
inhibitors (eg, anastrozole or letrozole).2 3
Tamoxifen is a selective oestrogen receptor
modulator, whereas aromatase inhibitors
(AIs) reduce oestrogen synthesis by blocking
conversion of androgens into oestrogen.
Clinical trials have shown that tamoxifen
reduces the risk of disease recurrence by
11.8% and mortality by 9.2% over 5 years,
and AIs are associated with even lower recur-
rence rates in postmenopausal women.4 5
Guidelines recommend 5 years of adjuvant
endocrine therapy, although recent trials
have shown reduced all-cause and breast
cancer-specific mortality in patients using
tamoxifen for 10 years compared with five.3 6
Extended treatment with adjuvant AIs for at
least 8 years postdiagnosis has also been
advocated.7 With recent guidelines support-
ing the use of tamoxifen for breast cancer
prevention and successful chemoprevention
with anastrozole in postmenopausal women,
the issue of adherence to endocrine therapy
now extends to the chemopreventive
setting.8 9
Strengths and limitations of this study
▪ This is one of the few studies which have asked
women to talk about their experiences of taking
adjuvant endocrine therapy for breast cancer.
▪ We found that women seek to be adherent but
some will miss tablets without realising the
potential consequences.
▪ The impact of severe side effects does not
necessarily affect adherence, as women’s belief
that taking the medication reduces their risk of
recurrence outweighs these negative effects.
▪ Not all women who experience side effects will
seek advice and support. Opportunities for moni-
toring adherence to and managing symptoms of
adjuvant endocrine therapy are underutilised.
▪ Women with low adherence and those who were
premenopausal were under-represented in this
study.
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Despite the survival benefit, one-third to a half of
women do not complete even the recommended 5-year
adjuvant course.10–18 Between 19% and 28% of women
prescribed adjuvant endocrine therapy in the community
miss at least one out of five daily doses, with a consequent
associated increased risk of breast cancer recurrence and
mortality.11 13–15 19–21 Recent work from the authors has
demonstrated that women with low adherence to adjuvant
endocrine therapy had an increased risk of mortality
(HR=1.3, 95% CI 1.16 to 1.51, p<0.001), reduced
quality-adjusted life years (QALYs) and increased medical
costs (£5970, 95% CI £4644 to £7372).14 15
Adjuvant endocrine therapy with either tamoxifen or
an AI has a significant side effect profile.22 Side effects
commonly reported for tamoxifen include hot flushes,
weight gain and loss of libido, and less commonly
thromboembolic disease or endometrial pathologies. AIs
also cause hot flushes and have been associated with
arthralgia, increased fractures, rash and gastrointestinal
upset.23 24 A small qualitative study found that the side
effects experienced were not always felt to be worth the
perceived benefits of taking tamoxifen.25 Only 3% of
women attributed surviving at 3 years to adjuvant endo-
crine medication compared with 48% who felt that a
positive attitude was more important.26
The majority of studies examining adherence to adju-
vant endocrine therapy have focused on measuring non-
adherence in terms of number of pills taken and the
impact on recurrence and mortality.27 These aggregated
numerical data fail to capture the diverse patterns of
adherence or the complex factors which may lead to
breaks in adherence, well recognised as a feature of
treatment for other chronic conditions.28
Although there is limited evidence to support this
assumption, side effects are generally considered to be the
main reason for women not continuing adjuvant endo-
crine therapy.29–31 Other factors linked to social support,
lack of information and beliefs about cancer, as well as the
complexities associated with taking medications for other
chronic conditions are also thought to contribute to inten-
tional non-adherence.32 33 Gaining an in-depth under-
standing of the important elements which contribute to
women’s beliefs about the use of this medication and
examining factors which influence adherence/non-
adherence will enable us to develop insights into how best
to support women to continue taking long-term adjuvant
endocrine therapy. This qualitative study aimed to explore
women’s experiences of taking adjuvant endocrine
therapy; their understandings and reasons for taking or
not taking medication and the factors which influenced
adherence or non-adherence and the information and
support they received or desired.
METHODS
Design
The study was conducted in outpatient clinics at two hos-
pitals within the NHS Tayside health board in Scotland.
Recruitment and data collection were carried out
between January 2013 and May 2013. Semistructured
face-to-face interviews were conducted using a topic
guide (box 1). This allowed sensitive exploration of each
individual’s experience of their disease and treatment,
and permitted flexibility for the patient to introduce
new topics, while allowing collection of data on core
themes.
Participants and procedures
Participants were women who had been diagnosed with
primary breast cancer and who were attending out-
patient clinics for routine surgical or oncology follow-up
between 1 and 5 years after diagnosis. We aimed to
recruit 24–30 participants to achieve variation in our
sampling to include a range of different times since
diagnosis, different adjuvant endocrine therapies and
where possible varying rates of self-reported adherence
to treatment.
The researcher (RD) attended 14 surgical and oncol-
ogy outpatient clinics in hospital 1 and hospital 2
between 24 January 2014 and 18 April 2014. The major-
ity of these clinics were in hospital 1 as the throughput
of patients was smaller in hospital 2. After routine clinic
appointments, staff informed all women that a research
study was being carried out into women’s experiences of
tamoxifen and aromatase inhibitors. Those who agreed
were then introduced to RD (an experienced health ser-
vices researcher but no clinical background in breast
cancer) who briefly explained the study and provided
written information to those women who expressed an
interest in participating. As recruitment proceeded the
purposive sampling criteria were increasingly applied in
order to achieve maximum variation. A follow-up phone
Box 1 Topic guide
Areas to explore
1. Perceptions and beliefs about breast cancer:
For example, set context by discussing breast cancer diagnosis,
illness perceptions and how this has varied by time.
2. Experience and understanding of breast cancer and its
treatment
For example, explore their understanding of treatment: what
it is for, what it does, how important it is for them.
3. Beliefs, feelings and experiences about taking adjuvant
endocrine therapy
For example, general views about taking medication, specific
views about this medication, any concerns or side effects.
4. Medication routines information and support received
For example, who have they had specific discussions about
hormone medication with: for example, surgeon, BCN, GP,
pharmacist, peers, what did they think about these discus-
sions, did they have any influence on medication use.
5. Factors which influence or might influence ongoing medica-
tion adherence or non-adherence
For example, advice, support, information, routines, percep-
tions, side effects, attitudes towards cancer
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call, at least 24 h after the clinic, allowed RD to provide
additional information and set up an interview. Women
were offered the choice of being interviewed at home or
in a university location.
Data analysis
Interviews were recorded, transcribed by a professional
transcription company, anonymised and checked for
accuracy by RD. Analysis drew on the constant compari-
son method applied within the framework approach,
therefore enabling us to check that data saturation had
been reached.34 NVivo was used to manage the data.35
AH and RD developed a coding framework on the basis
of the topic guide and initial analysis of transcripts. In
our analysis we drew on, but were not limited by, the
work of Horne and Weinman36 who use illness represen-
tation theory to show that while illness beliefs play a role
in adherence, patients’ beliefs about the necessity of
their treatment also have a direct role in medication
adherence.
The first five interviews were coded by AH and RD
independently. All codes and coded texts were then
reviewed by AH and RD to ensure concordance was
reached. MW and RD then independently coded three
more transcripts until the coding frame was further
refined. Coding matrices were then developed in order
to identify any patterns in the data (for an example of a
coding matrix see online supplementary file). Regular
meetings consisting of all authors and a patient repre-
sentative were held to discuss all aspects of study devel-
opment, analysis and dissemination.
RESULTS
Forty-nine women who met the eligibility criteria were
identified and asked to participate in one-to-one inter-
views. Of these, 17 women declined to take part for
reasons which included not wanting to think about
cancer or being too busy with caring commitments or
other illnesses. Of the remaining women, two who had
initially agreed to participate, and who had indicated
that they did not take their medication as prescribed,
were not at home at the time arranged for their inter-
views. Neither could be contacted to arrange a new date.
Thirty women participated in semistructured one-to-one
interviews (20 in women’s homes and 10 in an academic
setting) taking an average of 51 min per interview
(range 24–102 min).
All of the participants had been prescribed tamoxifen,
anastrozole or letrozole daily. Five out of 30 women
described missing one or two tablets now and then, 9
women had stopped temporarily (n=6) or permanently
(n=3), either following clinical advice or of their own
volition. The remaining 16 women said they had taken
their medication every day. Clinical and sociodemo-
graphic characteristics of the sample are shown in
table 1.
Analysis identified eight key themes: lifeline to being
cancer free; doctor knows best; it’s a religion; remember-
ing not to forget—got the routine; living with the side
effects—I am still alive; no one’s ever asked if I am still
taking it; keeping it to themselves—everyone’s different;
appropriate expertise. These are presented with quotes
(labelled with participant number, age range and adju-
vant endocrine therapy prescribed) used to illustrate
typical and/or divergent responses under the specific
areas explored within the interviews. These have been
grouped into three main areas: reasons for taking adju-
vant endocrine therapy; experiences of taking adjuvant
endocrine therapy; perceptions of and need for support.
Factors which influence adherence or non-adherence
have been subsumed into reasons for and experiences
of taking adjuvant endocrine therapy.
Reasons for taking adjuvant endocrine therapy
When asked about their reasons for taking adjuvant
endocrine therapy participants’ responses were remark-
ably consistent.
Table 1 Participant demographics
Number of
women (%)
Age group at interview
<50 years 2 (7)
50–64 years 15 (50)
≥65 years 12 (40)
Age unknown 1 (3)
Type of hormone therapy
Tamoxifen 16 (53)
Aromatase inhibitors 10 (33)
Tamoxifen and aromatase inhibitors 4 (13)
Year of treatment
First 3 (10)
Second 4 (13)
Third 13 (43)
Fourth 7 (23)
Had stopped taking adjuvant endocrine
therapy <6 months before recruitment
3 (10)
Additional treatment type
Surgery only 6 (20)
Surgery and chemotherapy 3 (10)
Radiotherapy only 1 (3)
Surgery and radiotherapy 15 (50)
Surgery, chemotherapy and radiotherapy 5 (17)
Menopausal status at diagnosis
Premenopausal 3 (10)
Perimenopausal 7 (23)
Postmenopausal 17 (57)
Unknown 3 (10)
Outpatient clinic recruitment source
Surgical (hospital 2) 7 (23)
Oncology (hospital 1) 12 (40)
Surgical (hospital 1) 11 (37)
Cancer detection method
Routine screening 12 (40)
Self-referral 18 (60)
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Almost half of the women acknowledged the import-
ance of endocrine therapy in terms of the protection it
offered against cancer recurrence, recognising it as the
next necessary stage of their treatment: a Lifeline to being
cancer free. They also felt that they would not have been
prescribed this medication if it was unnecessary and
respected clinicians’ knowledge: Doctor knows best
(box 2).
Experiences of taking adjuvant endocrine therapy
The theme Remembering not to forget indicated the import-
ance many women placed on taking adjuvant endocrine
therapy as prescribed, every day. These routines gener-
ally consisted of a combination of keeping tablets some-
where they would be seen and/or taking the medication
at a very specific time each day. However, having a
routine was no guarantee that they would remember to
take their tablets; one-fifth of the women still described
forgetting occasionally. Some took their tablets late if
they discovered they had forgotten, while others justified
missing one or two as they felt this would make little dif-
ference to the efficacy of the medication. While some
women described going to extremes to ensure they took
the medication at a particular time, others were less con-
cerned (box 3).
Seventeen women were sure they had never missed a
tablet or had detailed explanations for missing any: It’s a
religion (box 3).
Adherence was not without personal cost for some.
The theme Living with the side effects—I’m still alive illus-
trates how women’s beliefs about the efficacy of the
medication, and their desire to continue with it as
advised by health professionals, were key factors in their
ongoing adherence. Women were asked if side effects of
these medications had been discussed with them at the
time of being prescribed and while most were aware of
hot flushes and joint pains none mentioned any of the
more severe side effects associated with either tamoxifen
or AIs. One woman described being investigated for
endometrial cancer and the majority of women pre-
scribed an AI indicated that they had bone scans.
Several described that one of the side effects of AIs
could be loss of bone density or ‘brittle bones’. However,
they did not raise this as a major consideration in either
taking or continuing with AIs.
They said that it would remove the, I can’t remember the
name it’s something, oh dear, they did tell me what the
Letrozole did and I can’t remember what it removes but
then if that is removed it can cause brittle bones…Which
is why I’ve got the other tablets, they told me that I did
have brittle bones and that I could if I fell I could you
know break quite a lot so they prescribed the Alendronic,
they didn’t tell me how bad the brittle bones were, I
asked the doctor and he said no I don’t have that infor-
mation. (Participant 22, age ≥65, letrozole)
More than half found the side effects they experi-
enced unproblematic or did not attribute their symp-
toms directly to adjuvant endocrine therapy.
It’s painless, I don’t have any side effects. It’s been very
easy. I consider myself really lucky. But if it’s working,
then I’ve got off easy. (Participant 13, age ≥65,
anastrozole)
Well, I felt more emotional, I suppose I felt more
PMT-ish …I feel I get a bit panicky, but that’s, maybe, just
old age, I don’t know. Because you can’t blame things on
what you’re taking. (Participant 1, age age ≥65, anastro-
zole which was changed after 3 months to tamoxifen fol-
lowing a bone scan)
However, the list of side effects experienced and attrib-
uted to adjuvant endocrine therapy was extensive, and
more than a third described the profound impact these
had on their daily lives (box 3). Several gave graphic
descriptions of extreme menopausal symptoms (hot
flushes and night sweats, joint pains, vaginal dryness,
loss of libido, weight gain, hair loss, insomnia) as well as
suicidal feelings, fatigue, allergic reactions and severe
nausea. One woman’s side effects led to her having
investigations to rule out endometrial cancer.
Box 2 Reasons for taking adjuvant endocrine therapy
Lifeline to being cancer free
I see my tamoxifen as the lifeline to being cancer free.
(Participant 27, age range 50–64, tamoxifen)
The way I see it is that this is my chance. It may be a small
chance but I see it as being a chance to diminish my chances of
its returning… (Participant 3, age range 50–64, letrozole)
…my body has already proved I can get breast cancer…if I’ve got
to be on a tablet for 5 years that’s going to put a protection
around it, it hopefully won’t happen again… (Participant 15, age
range ≤49, tamoxifen)
So I think I’m sure that’s what they said that the surgery would
cut it out, the radiotherapy would kill it externally although it did
go in and the tablet, the anastrozole was to try and prevent the
cancer cells reforming. (Participant 21, age range ≥65,
anastrozole)
Doctor knows best
I just accept what the doctor said, you know. (Participant 11,
age range ≥65, taking tamoxifen which was changed to
anastrozole)
I suppose just because the consultant explained that that would
be part of the on-going treatment and so because I’d gone
through all the other bits, there was no real reason to then say I
wasn’t going to take letrozole. (Participant 9, age range ≥65,
taking letrozole)
…you get no benefit that you can see, you just have to take
peoples word for it (Participant 24, age range ≥65, taking
letrozole)
I mean because I understand in general terms what’s going on
and you know if I wanted to I could go and investigate you know
become a complete nerd about letrozole and all the different you
know, but basically because I trust the clinical advice I’m being
given. (Participant 23, age range 50–64, taking letrozole)
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Unless advised to stop by health professionals, those
women who described their treatment having a negative
impact on their daily lives were still prepared to tolerate
this in order to reduce the threat of recurrence and death.
I’m still alive but there’s huge consequences that I live
with every day and the knock-on effect…makes it really
difficult and, you know, if you were to ask me, would I
still ... going back, would I still go on tamoxifen?
Absolutely because I wouldn’t risk cancer coming back...
(Participant 26, age range 50–64, tamoxifen)
Perceptions of and need for support
Two themes were identified which indicated that women
would not necessarily seek out additional support net-
works and that some experienced a lack of consistent
monitoring of whether they were taking or coping with
their medication; Keeping it to themselves—everyone’s
different, No one’s ever asked if I’m still taking it and
Appropriate expertise (box 4).
Although 7 women did remember being asked about
taking adjuvant endocrine therapy, 14 others were either
sure they had not been asked or could not recall being
been asked whether they were continuing with their
medication or whether they were experiencing any pro-
blems, either at follow-up clinics or by their general
practitioner (GP).
However, where women did discuss the side effects they
were experiencing, they were supported to explore ways of
reducing their symptoms. Three women were advised to
take breaks in treatment; one by the GP, who stopped her
tamoxifen because of side effects which included conjunc-
tivitis and whole-body itching. This woman’s medication
was restarted as soon as she attended for her routine
follow-up appointment, approximately 3–5 months after
the GP had told her to stop. The other two women were
advised to stop at follow-up clinics (1 for 3 weeks and 1 for
Box 3 Experiences of taking adjuvant endocrine therapy
Remembering not to forget—got the routine
Got the routine, I take the dog out, come back, have all the, have a wee drop breakfast and have the rest of the pills. (Participant 22, age
range 50–64, letrozole)
I was away to New York before Christmas time, well, in November. So, I had to…I was trying to, I was taking it…through the night.
Because I wanted to keep it in the 24 hour clock. So, it was…I think it was four o’clock in the morning… (Participant 5, age range 50–64,
tamoxifen)
If I’m day shift I am taking them at seven, if I am night shift, I’m taking them at 8 in the morning. So I am keeping them as near as possible
to the twenty four hour period. (Participant 16, age range 50–64, tamoxifen)
There are quite a few times that I forget…There is sometimes that I go to the box and I have missed the day before, but I am bad for that,
because if I discover that, I take them, and then I take them again, twelve hours later. (Participant 15, age range ≤49, tamoxifen)
I’ve sort of assumed that if you’re taking a drug for five years it isn’t going to really make a lot of difference you know it’s not as if these
poor old cells are suddenly going to start pumping the stuff out because you took it eight hours late. (Participant 23, age range 50–64,
letrozole)
It’s a religion
No, it’s a religion, you know, it’s ... I have my little blue box of pills that’s counted out every day and it’s in there. (Participant 13, age ≥65,
anastrozole)
Never missed it, never, it’s in my head you know it’s something I have to do. (Participant 21, age range ≥65, anastrozole)
Well, I wouldn’t forget my anastrozole, that’s for sure, it’s like my best friend. (Participant 11, age range ≥ 65, taking tamoxifen which was
changed to anastrozole)
Living with the side effects—I’m still alive
…if I was a car engine it had just sucked all the oil out of my entire body so my knees, my shoulders ache like they’ve never ached before.
(Participant 8, age range 50–64, tamoxifen)
…it was affecting my life quite badly; I mean you go out for a meal and you are sitting and the water is lashing off you, and you have only
had a cold drink. It’s really quite debilitating at times. (Participant 16, age range 50–64, tamoxifen)
Anyway immediately I noticed the hot flushes and they were terrible to start with. I was sometimes getting 7 or 8 a night and just drenched
and just waking up, I couldn’t sleep. (Participant 14, age range 50–64, tamoxifen)
I took it and I took it every day and I cried very day and I didn’t want to live, wanted to die. (Participant 19, age range ≤49, tamoxifen)
I was just exhausted and it was just getting worse and worse and I realised that I wouldn’t be able to work and I couldn’t function and I
couldn’t see myself getting through five years of that. (Participant 30, age range 50–64, tamoxifen before stopping with support of health
professionals)
I had quite a busy job…So I stopped that so you know I really could pretty much say I’m doing hardly anything and yet I’m still exhausted
all the time. (Participant 18, age range 50–64, letrozole)
We’re having to downsize our house so that we can accommodate the fact, because I would rather live in a smaller house costing less
money, so that I have the option that if I’m still not well enough I don’t have the pressure of having to go back to work. (Participant 26, age
range 50–64, tamoxifen)
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6 weeks) were supported by breast care nurses during this
period and also when they resumed endocrine therapy. All
were aged between 50 and 64 years and were at different
stages of menopause. Two were prescribed tamoxifen and
one, letrozole. After their temporary breaks, all three
resumed taking the medication as prescribed, although
they all experienced ongoing side effects.
Three women stopped adjuvant endocrine therapy
completely after being advised to do so at follow-up
appointments. They were told that they were at ‘low risk’
of recurrence and therefore could stop the medication
if they felt that their side effects were too problematic.
All acknowledged the clinical expertise of the health
professionals and did not describe any ongoing con-
cerns related to stopping or feeling at greater risk of
recurrence.
It was based on the doctor having said that the risk was,
you know, the benefits were minimal and that if I didn’t
take it, it would ... really, I understood that it wouldn’t
really matter... and I think I remember reading some-
where or hearing somewhere that they were kind of over-
prescribing. Would that be right? (Participant 28, age
range ≥65, taking tamoxifen before stopping with
support of health professionals)
Box 4 Perceptions of and need for support
Keeping it to themselves —everyone’s different
So I went and looked up, there were lots of forums and things on line, I mean and the truth is that when you read these forums, you
really have to be aware that you’re mainly going to read stories from people who have had problems. (Participant 30, age range 50–64,
tamoxifen before stopping with support of health professionals)
Yes, but they do tell you people can have the same type of cancer as you and all the details be the same and yet the treatment will be differ-
ent, the outcomes will be different and the experience will be different so it’s not, you can’t say well I’ll speak to somebody else who’s had
the same thing I’ll know exactly because you don’t. (Participant 18, age range 50–64, letrozole)
And some of them were like the hot flushes, things like that, which people were talking about, this will happen with the tamoxifen, so I think
in a way, in my head, it was kind of, well that is nothing new, I’m getting that already, I’ve been through, so if that is happening, I know
what it is going to feel like... I know what a hot flush felt like, you know what I’m meaning? And so I just didn’t I never really spoke to
anybody about it. (Participant 15, age range ≤49, tamoxifen)
No one’s ever asked if I’m still taking it
No one’s ever asked if I’m still taking it. (Participant 1, age range ≥65, anastrozole which was changed to after 3 months to tamoxifen fol-
lowing a bone scan)
Nobody’s asked me about it since. And the Doctor [GP] knows that I’m on it, but we never discuss it. (Participant 2, age range ≥65,
letrozole)
No, they just said I had to speak about what I’m worrying about and I say nothing at all. (Participant 6, age range ≥65, anastrozole)
I can’t remember whether she asked about…I mean I think they ask if I’m taking it but there’s not a great deal of stress laid on it, I don’t
think. (Participant 9, age range ≥65, letrozole)
…I don’t know if they ask me if I’m still taking it. I mean, I’m not sure. (Participant 12, age range 50–64, tamoxifen)
No, it wasn’t really spoken about very much. But on the other side of it, I wasn’t really wanting to talk about it. (Participant 15, age range
≤49, tamoxifen)
Appropriate expertise
I’m not meaning this badly, but the GPs and everything; they probably know about chemotherapy and everything, but the people at
Hospital X, they are dealing with it all the time…if I say something to the Doctor I might make a comment but then have to explain it a
wee bit, whereas if I am in Hospital X they know exactly what I am talking about. (Participant 15, age range ≤49, tamoxifen)
… I get on well with him and I find him very good but I got the impression that he [GP] didn’t want to be involved in the cancer issue, he
said something to the effect of ‘oh that was for the hospital to deal with but how are you in regard to your other medication’ and this sort of
thing, it was as if that’s a completely separate thing that the hospital will deal with. (Participant 18, age range 50–64, letrozole)
Yes, they’ve got a little consultation room that you can go in privately and talk to them [Pharmacist] and, you know, I think these women are
very smart and they know their drugs. (Participant 13, age range ≥65, anastrozole)
Yes I mean I wouldn’t have a problem with that, either that or the doctor you know I would chat to the doctor but yes I would go to the
chemist if I had any problems with the prescriptions or the tablets. (Participant 22, age range ≥65, letrozole)
With the hot flushes the Pharmacist did suggest instead of taking it in the morning, to try taking it at night to see if it made any difference.
But I found it made the flushes, if anything, worse at night. So I went back to taking it in the morning. (Participant 16, age range 50–64,
tamoxifen)
The relationship isn’t there…I wouldn’t have thought about going to see the pharmacist to talk about my side effects with any medications,
I go to the GP about that. (Participant 20, age range not known, tamoxifen)
No I wouldn’t have thought of the pharmacist as a place to go about this I mean I would you know I would ask the pharmacist what cough
medicine to buy or something like that. (Participant 23, age range 50–64, letrozole)
They’re [pharmacists] not interested, all they’re interested when you do your repeat prescriptions are your quantities. (Participant 3, age
range 50–64, letrozole)
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You’ve got three choices, we could change it to another
one, or we could halve it, or we could take you off them
altogether and when he said that he went, You could do
that, you dinnae need them he says Your kind of cancer
wasna bad and I went Right, I’m stopping them.
(Participant 29, age range 50–64, taking tamoxifen
before stopping with support of HPs)
That just made it very easy because he didn’t seem par-
ticularly bothered about my not taking it…and I was
thinking well maybe if we’d had this discussion six
months ago, I might have just not taken it. Participant
30, age range 50–64, taking tamoxifen before stopping
with support of health professionals)
Three women were intentionally non-adherent for
short periods of time. They took breaks in treatment
because of the side effects they were experiencing and
did so without seeking advice.
So I actually stopped, I didn’t take any for maybe just two
days or something but I must have contacted the hospital
or something,…I can’t remember if the Macmillan nurse
told me to come in…but anyway they said we don’t think
it can be that [the side effects are due to adjuvant endo-
crine therapy] you’d better start them again. (Participant
17, age range 50–64, letrozole)
I never went to the doctor I just took it upon myself to
stop the letrozole and I thought I’m going to start them
again, so I started taking them again and I although I felt
little bits of nausea it wasn’t nearly as bad…so I’ve just
kept on taking them since then and everything seems to
be okay… (Participant 22, age range ≥65, letrozole)
…I was trying to keep it going till I got to the clinic but
because I felt I couldn’t drive my car I stopped it because
it was only about ten days before my clinic appoint-
ment ... But you know I mean I knew that really ten days
off it wasn’t going to make any difference you know in
the long term, so then I got tamoxifen and I’m fine with
that... (Participant 24, age range ≥65, letrozole then
changed to tamoxifen)
None of the women described any discussions about
or the use of concomitant medication or other
approaches to ameliorate the side effects of the endo-
crine therapy.
Even with limited opportunities available to discuss
the challenges of taking adjuvant endocrine therapy
most women still continued to take this medication
unless advised otherwise. Indeed many described techni-
ques they used to ensure that they did not forget to take
their tablets.
The final theme Appropriate expertise illustrated which
women might approach to discuss questions about medi-
cation. Women said they would go to their GP to get
their first prescriptions for adjuvant endocrine therapy.
Most indicated that they would visit their GP with
general concerns about their medication. However, deci-
sions about changes to adjuvant endocrine therapy,
breaks in treatment or stopping treatment were always
made or endorsed by hospital-based health profes-
sionals. There were indications that GPs tended to leave
any medicine monitoring to their hospital colleagues.
Adjuvant endocrine therapy was generally added to a
repeat prescription system after the initial GP appoint-
ment. Repeat prescriptions were either collected from
pharmacies or delivered by pharmacies to the women’s
homes. Nearly half of the participants indicated that
they either had or would ask the pharmacist about issues
related to adjuvant endocrine therapy; however, there
was a range of views about the degree to which pharma-
cists were equipped to provide appropriate support or in
the case of some women it had never occurred to them
to talk to the pharmacists about concerns related to
taking adjuvant endocrine therapy.
So, while women acknowledged the importance of this
medication and were prepared to put up with many of
the side effects, they appeared to be given limited
reassurance and reinforcement and were seldom offered
or sought out the opportunity to discuss taking adjuvant
endocrine therapy.
DISCUSSION
This study demonstrates that women go to considerable
lengths and make considerable sacrifices to take their
medication. Many women reported side effects of adju-
vant endocrine therapy, some of which were debilitating,
but these were generally accepted as a price to pay for
protection against recurrent disease. None of the
women in our study perceived themselves as having low
adherence, and they were responsive to healthcare pro-
fessionals’ advice to continue, take a break or stop medi-
cation. Few described having had discussions with health
professionals about side effects in the context of adher-
ence to endocrine therapy. The approaches women took
to achieve adherence differed. Some ensured that their
tablets were taken within a small specified time frame,
for example, by staying up until the early hours of the
morning to take the medication while abroad. Other
women believed they were fully adherent and had imple-
mented routines to help them remember, but admitted
they sometimes missed tablets. Given that recent studies
have indicated that missing only a few tablets can have
an impact on mortality, our findings suggest that there
are women who would possibly benefit from closer mon-
itoring and more discussion about side effects, alterna-
tive medication or self-management strategies to enable
informed and effective adherence.15 In addition, there
is in vivo preclinical evidence to support the advice to
‘take a break’ from medication which is being applied to
the extended adjuvant setting. The SOLE study tests
extended adjuvant letrozole, continuous for years 5–10
versus 9 months on/3 months off letrozole for years
5–10 postdiagnosis in postmenopausal ER positive breast
cancer. This may provide support for a break in treat-
ment, at least in the extending adjuvant setting, as it
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compares intermittent versus continuous letrozole.37
Our findings certainly indicate that some women would
benefit from having time to discuss in more detail why
full adherence is important in reducing their risk of
breast cancer recurrence.
As found in other studies, nearly all the women inter-
viewed in this study believed that taking the prescribed
adjuvant endocrine therapy would reduce their risk of
breast cancer recurrence and extend their lives.38
Perceptions of benefit are important in ‘decisional
balance’ scores whereby the advantages (pros) of taking
tamoxifen are weighed against the risks (cons) of not
taking it, as an indicator of ongoing adherence behav-
iour.39 Such decisions are supported by theories based
on the common-sense self-regulation model.40 These
demonstrate how patients’ beliefs about the importance
or ‘necessity’ of a medicine to control or treat an illness
are combined with the level of ‘concern’ they have
about the side effects of a drug, to influence adherence
to the prescribed medication.41–43 Our data are consist-
ent with the ‘necessity-concerns’ model. Women who
were told to stop medication to alleviate side effects
because they were at ‘low risk’ accepted this decision,
perhaps because their concerns outweighed their per-
ceptions of necessity. This group reported being dili-
gently adherent to their medication until they were
given permission to stop. Others, who stopped without
advice because of the side effects they experienced, but
were advised to restart endocrine therapy, appeared to
be realigning their necessity beliefs in the light of the
professional guidance. Studies in chronic disease have
found that patients’ beliefs about their medication affect
intentional and non-intentional non-adherence.44 45
However, those who encounter conflicting medication
information are known to be less adherent.45
Our findings suggest that a patient-centred approach
that takes individual circumstances and beliefs into
account is likely to facilitate adherence.46 Other studies
have found that specialist breast care nurses have an
important role to play in providing information and sup-
porting adherence.47 As evidence for the long-term con-
sequences of cancer treatment increases, specialist
nurses are likely to play a greater role in educating
women about the benefits and risks of hormone
therapy.48 Interestingly, less common but serious risks of
taking adjuvant endocrine therapies in the longer term, for
example, bone loss, cardiovascular disease (in AIs) or endo-
metrial cancer were not raised by any women in this study,
and did not appear to be major considerations for adher-
ence. Data from current studies such as the SOLE trial com-
paring continuous versus intermittent (9 months letrozole,
3 months no letrozole) from years 5 to 10 for women at
risk of recurrence are likely to improve our understanding
of the risks and benefits of long-term therapy.
There was little evidence of consistent, routine moni-
toring of medication either in the community or at
follow-up clinics. Although GPs and pharmacists could
play an important role in supporting adherence and
monitoring the side effects of treatment they seldom did
so, and the women themselves felt that the hospital
team were more knowledgeable about breast cancer and
its treatment.49 50 However, the trend towards shorter
hospital-based follow-up (with discharge at 3 years
recommended by NICE) combined with the emerging
evidence to support tamoxifen use for 10 years and AIs
beyond 5 years, suggests that any intervention to
enhance adherence will need to be situated in the com-
munity rather than the secondary care setting.51 Such
models may also go some way in addressing inequalities
in access and cancer outcomes in people from lower
economic groups and those with low literacy who may
struggle to access specialist centres and fully understand
the requirements of successful treatment, including pro-
longed and consistent adherence to medication.52 53
Community pharmacy interventions have been shown to
be successfully implemented in other settings.54 This
study suggests that the role of community pharmacists in
supporting adjuvant endocrine therapy needs to be
further developed.
There are a number of limitations to this study. This
study was conducted in only two centres with the major-
ity of participants recruited from a single centre. Women
with low adherence and those who were premenopausal
were under-represented in this study. However, field
notes made at the time indicate that most eligible
patients were approached, staff were seen to introduce
the study in a neutral way and there were few women
who did not attend on the day of the clinic. It would be
naïve to presume that intentional non-adherence is a
myth and our study may not have reached those patients
who stop taking adjuvant endocrine therapy without the
knowledge of their clinician or who may already have
been lost to follow-up for a variety of reasons.52 53
Furthermore, it is likely that our sample included
women who might be classed as having low adherence
(taking <80% of prescribed tablets) in quantitative
studies. Several women had been advised to take
extended breaks or stop their medication, some who
had stopped for periods of time without advice and
others who frequently missed one or two tablets
accounted for approximately half of our sample. They
may represent the group which has been classed as
having ‘low adherence’ in previous studies.
This work reinforces other studies that show those
living with cancer are reticent in talking about adverse
symptoms because they see them as insignificant in com-
parison to the cancer.55–57 Current initiatives to enhance
recovery and self-management may address some of
these issues, but these are not yet universally available to
survivors of breast cancer.58 Such initiatives include: hol-
istic needs assessment using a screening tool which
encompasses a comprehensive range of side effects and
concerns; the cancer care review which promotes a
structured discussion between the GP and person with
cancer; and the extension of pharmacists’ roles to
include advice and support to cancer survivors (eg,
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Macmillan Information Centres located in local pharma-
cies); all of which may serve to improve support for
women taking adjuvant endocrine therapy.59 60 It is
important that tailored initiatives are made more access-
ible if we are to improve and support adherence. At
thevery least, health professionals who encounter women
on endocrine therapy should be encouraged to ask rou-
tinely about side effects, experiences and adherence
issues, rather than expecting women to initiate discus-
sions. Further qualitative studies targeting women who
are known to be non-adherent would enhance the knowl-
edge base in this area. Innovative and theory-based inter-
ventions are needed to support self-management and
enhance adherence, with the ultimate aim of improving
long-term survival. Finally, improved methods of measur-
ing adherence are required for large-scale studies.
CONCLUSIONS
There is increasing evidence that adherence to adjuvant
endocrine therapy for primary breast cancer impacts on
survival, QALYs and the economics of cancer
care.4 5 11 13–15 19–21 Adherence is likely to become more
relevant as the evidence mounts for longer duration use
of tamoxifen (from 5 to 10 years) and use of AIs beyond
5 years.3 6 7 In addition, the trend towards chemopreven-
tion in women at risk of breast cancer using tamoxifen8
(NICE 2013) or anastrozole suggests that the issue of
adherence may extend to ‘healthy’ populations.
There is a clear need to communicate consistently and
effectively about endocrine therapy and its effects, as
well as to offer ongoing support and advice in hospital
and community settings. The future challenge will be to
design, test and implement appropriate and effective
interventions to improve adherence to adjuvant endo-
crine therapy in women who have survived the initial
diagnosis of breast cancer, but remain at risk of recur-
rent disease.
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